Our result showed that the patient with high BRM had a significantly worse survival than those without (5-year OS: 9.8 vs. 43.8%, p=0.009), suggesting BRM/BAF in pancreatic cancer may contribute to tumor progression. Here, BANF1 is linked to pancreatic neoplasm.